IJCS | Volume 31, Nº6, November / December 2018

660 8. Lim SL, Lam CS. Breakthrough in heart failure with preserved ejection fraction: are we there yet? Korean J Intern Med. 2016;31(1):1-14. 9. vanHeerebeek L, PaulusWJ. Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J. 2016;24(4):227-36. 10. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure syndrome. Circulation. 2011;123(18):2006-14. 11. Mesquita ET, Jorge AJ, Souza Junior CV, Cassino JP. Systems biology applied to heart failure with normal ejection fraction. Arq Bras Cardiol. 2014;102(5):510-7. 12. Shah SJ, Katz DH, Deo RC. Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10(3):407-18. 13. Joyner MJ. Precision medicine, cardiovascular disease and hunting elephants. Prog Cardiovasc Dis. 2016;58(6):651-60. 14. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56(11):845-54. 15. Tan YT, Wenzelburger F, Lee E, Heatlie G, Leyva F, Patel K, et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol. 2009;54(1):36-46. 16. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developedwith the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. 17. Little WC. Diastolic dysfunction beyond distensibility: adverse effects of ventricular dilatation. Circulation. 2005;112(19):2888-90. 18. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131(14):1247-59. 19. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507-15. 20. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013;128(10):1085-93. Erratum in: Circulation. 2013;128(24):e465. 21. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670-9. 22. SmithCS, Bottomley PA, Schulman SP, GerstenblithG, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation. 2006;114(11):1151-8. 23. Phan TT, Abozguia K, Nallur ShivuG, Mahadevan G, Ahmed I, Williams L, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009;54(5):402-9. 24. Baicu CF, ZileMR, Aurigemma GP, GaaschWH. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation. 2005;111(18):2306-12. 25. Napoli C, Grimaldi V, De Pascale MR, Sommese L, Infante T, Soricelli A. Novel epigenetic-based therapies useful in cardiovascular medicine. World J Cardiol. 2016;8(2):211-9. 26. Berezin A. Epigenetics in heart failure phenotypes. BBA Clin. 2016 May 30;6:31-7. 27. Marín-García J, Akhmedov AT. Epigenetics of the failing heart. Heart Fail Rev. 2015;20(4):435-59. 28. Schiano C, Vietri MT, Grimaldi V, Picascia A, De Pascale MR, Napoli C. Epigenetic-related therapeutic challenges in cardiovascular disease. Trends Pharmacol Sci. 2015;36(4):226-35. 29. Berezin AE. Circulating cell-free mitochondrial DNA as biomarker of cardiovascular risk: new challenges of old findings. Angiol. 2015;3(4):161- 3. 30. Kunkel GH, Chaturvedi P, Tyagi SC. Resuscitation of a dead cardiomyocyte. Heart Fail Rev. 2015;20(6):709-19. 31. Xiao D, Dasgupta C, Chen M, Zhang K, Buchholz J, Xu Z, et al. Inhibition of DNAmethylation reverses norepinephrine-induced cardiac hypertrophy in rats. Cardiovasc Res. 2014;101(3):373-82. 32. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 2007;100(3):416-24. 33. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269-79. 34. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73-90. 35. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014;35(40):2797-815. 36. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. 37. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The Perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-45. 38. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. 39. Kanwar M, Walter C, Clarke M, Patarroyo-Aponte M. Targeting heart failure with preserved ejection fraction: current status and future prospects. Vasc Health Risk Manag. 2016 Apr 15;12:129-41. 40. Biolo A, Rohde LE. O impacto dos polimorfismos genéticos e da farmacogenética na avaliação e manejo da insuficiência cardíaca. Revista da Sociedade de Cardiologia do Rio Grande do Sul. 2004;13(3):1-5. 41. Bohm M, Perez AC, Jhund PS, Reil JC, Komajda M, Zile MR, et al; I-Preserve Committees and Investigators. Relationship between heart rate and mortality and morbidity in the Irbesartan patients with heart failure and preserved systolic function trial (I-Preserve) Eur J Heart Fail. 2014;16(7):778-87. 42. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541-9. 43. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, et al. Cardiac structure and function and prognosis in heart failure with a preserved ejection fraction: findings from the echocardiographic study of the Treating Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014;7(5):740- 51. 44. Morner S, Hellman U, Suhr OB, Kazzam E, Waldenström A. Amyloid heart disease mimicking hypertrophic cardiomyopathy. J Intern Med. 2005;258(3):225-30. 45. Rapezzi C, Longhi S, Milandri A, Lorenzini M, Gagliardi C, Gallelli I, et al. Cardiac involvement in hereditary-transthyretin related amyloidosis. Amyloid. 2012;19 Suppl 1:16-21. 46. Nojima Y, Ihara M, Kurimoto T, Nanto S. Amyloid light-chain amyloidosis manifesting as heart failure with preserved ejection fraction Mesquita et al. HFPEF phenotypes Int J Cardiovasc Sci. 2018;31(6)652-661 Review Article